Komori
Earnings presentation4202Daicel CorporationMaterials and Chemicals

Presentation Materials for Results for the Fiscal Year Ended March 2025

In the fiscal year ended March 2025, higher sales volumes and the weaker yen drove increases in revenue and EBITDA, while operating income and net income declined due to trouble at the CO plant and higher depreciation. For the fiscal year ending March 2026, the company expects revenue to increase but plans for lower operating income due to the stronger yen and higher costs associated with capacity expansion.

Worth reading
72In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
70
億円（2026年3月期営業利益の前期比減少額）
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentation2025年3月期（2026年3月期業績予想も掲載）13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥5,865 million+5.1%
Operating profit¥610 million-2.2%
Ordinary income¥623 million-8.9%
Net income¥495 100 million -11.4%net income attributable to owners of the parent
Results for the three months of the current quarter
Net Sales
2025年3月期第4四半期¥1,540 million
Operating profit
2025年3月期第4四半期¥178 million
By segment2024年3月期・2025年3月期の1Q〜4Q単独の売上高・営業利益を掲載
Full-year earnings forecast
Fiscal year ending March 2026
Net Sales
¥6,000 million
Operating profit
¥540 million
Ordinary income
¥560 million
Net income
¥540 100 million net income attributable to owners of the parent
EBITDA
¥970 million
ROE
14.8 %
ROIC
5.4 %
ROA
6.6 %
EPS
¥203.67
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
2025年3月期は、売上高は対予想で減収、営業利益は微増。セグメント・製品別には計画以上と計画未達が併存
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
2025年3月期EBITDA
Volume impactPositive
Impact on pricing為替影響を含めるとプラス
Foreign Exchange Effects
¥76 million
COプラントトラブル・計画停止
¥-120 million
Operating profit for the fiscal year ended March 2025
Volume impact
¥37 million
Impact on pricing
¥40 million
Other
¥-91 million
Foreign Exchange Effects
¥76 million
EBITDA for the fiscal year ending March 2026
COプラントトラブル解消
¥120 million
繰越在庫影響
¥-92 million
経費差
¥-68 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
140 USD/JPY
メタノール・アジアスポット価格
330 USD/ton
Dubai crude oil
75 USD/bbl
Domestic naphtha
¥67,000 /kl
全世界自動車生産台数対前年度で微増を想定
POM中国市場成長率
3〜4
New initiatives
  • POM・LCP・COCの増産投資と新プラント稼働
  • セイフティ事業米国拠点の購買部門集約・物流効率化・現地調達化
  • 新規投与デバイスの医療機器薬事承認取得と販売体制構築
  • サンプルワーク用マイクロ流体デバイスプラントの導入
  • 半導体後工程へのフォトレジスト材料・接着剤の投入
  • 欧州EV用途電流遮断器の量産開始
  • Making 富山フィルタートウ a wholly owned subsidiary
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥1,024 million
    Year on year against the same period last year+6.5%
  • ROIC6.1 %
    Year on year against the same period last year-0.2%
  • ROE13.8 %
    Year on year against the same period last year-3.3%
  • ROA6 %
    Year on year against the same period last year-1.0%
  • EPS¥181.44
    Year on year against the same period last year-8.2%
  • PBR0.9 times
  • PER7 倍前後
Unit price and quantity metricsThese figures show sales broken down by price and volume.
セグメント別に数量差・単価差・単価差の内訳として為替影響を掲載。連結売上高では数量差143億円、単価差142億円、単価差内の為替影響210億円
Segment results
Medical and Healthcare
Net Sales
¥144 million+3.7%
Operating profit
¥3 million-67.0%
Smart
Net Sales
¥373 million+10.4%
Operating profit
¥-8 million
Safety
Net Sales
¥976 million+2.1%
Operating profit
¥39 million+31.4%
Materials
Net Sales
¥1,834 million+0.6%
Operating profit
¥296 million-27.4%
Engineering Plastics
Net Sales
¥2,480 million+9.3%
Operating profit
¥270 million+47.6%
Other businesses
Net Sales
¥58 million+1.6%
Operating profit
¥10 million+128.7%
Medium-term management plan targets
長期ビジョン『Daicel Vision 4.0』および中期戦略『Accelerate 2025』に沿った事業構造転換・再編を推進。具体的な目標値と実績の対比はNot disclosed
Financial targets
ROE
Fiscal year ended March 2025: actual13.8 %
Fiscal year ending March 2026 forecast14.8 %
ROIC
Fiscal year ended March 2025: actual6.1 %
Fiscal year ending March 2026 forecast5.4 %
ROA
Fiscal year ended March 2025: actual6 %
Fiscal year ending March 2026 forecast6.6 %
WACC
Fiscal year ended March 2025: actual4.4 %
Fiscal year ending March 2026 forecast4.4 %
Capital expenditures
695 億円2025年3月期実績）／710億円（2026年3月期予想
Annual Dividend
Fiscal year ending March 2025
Annual¥60 per share
End of period¥30 per share
Fiscal year ending March 2026 forecast
Annual¥60 per share
Interim¥30 per share
End of period¥30 per share
Payout ratio
PolicyDOE4%以上かつ総還元性向40%以上
Fiscal year ended March 2025: actual63.1 %
Fiscal year ending March 2026 forecast29.5 %
DOE
Fiscal year ended March 2025: actual4.4 %
Fiscal year ending March 2026 forecast4.1 %
Acquisition of treasury shares
Acquisition amount
¥150 million
Number of shares acquired
1,098 10,000 shares
Acquisition period2024年11月〜2025年2月
Treasury Share Cancellation
Number of Shares1,000 10,000 shares
消却前発行済み株式総数比3.61 10,000 shares
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period Covered2025年3月期（2026年3月期業績予想も掲載）
Net Sales¥5,865 million (YoY +5.1%)
Operating profit¥610 million (YoY -2.2%)
Ordinary income¥623 million (YoY -8.9%)
Net income¥495 100 million (net income attributable to owners of the parent) (YoY -11.4%)
Results for the three months of the current quarterNet Sales ¥1,540 million / Operating profit ¥178 million / By segment 2024年3月期・2025年3月期の1Q〜4Q単独の売上高・営業利益を掲載
Full-year earnings forecastSubject Fiscal year ending March 2026 / Net Sales ¥6,000 million / Operating profit ¥540 million / Ordinary income ¥560 million / Net income ¥540 100 million (net income attributable to owners of the parent) / EBITDA ¥970 million / ROE 14.8 % / ROIC 5.4 % / ROA 6.6 % / EPS ¥203.67
Self-assessment against the plan2025年3月期は、売上高は対予想で減収、営業利益は微増。セグメント・製品別には計画以上と計画未達が併存
Segment resultsMedical and Healthcare Net Sales ¥144 million (YoY +3.7%) / Operating profit ¥3 million (YoY -67.0%) / Smart Net Sales ¥373 million (YoY +10.4%) / Operating profit ¥-8 million / Safety Net Sales ¥976 million (YoY +2.1%) / Operating profit ¥39 million (YoY +31.4%) / Materials Net Sales ¥1,834 million (YoY +0.6%) / Operating profit ¥296 million (YoY -27.4%) / Engineering Plastics Net Sales ¥2,480 million (YoY +9.3%) / Operating profit ¥270 million (YoY +47.6%) / Other businesses Net Sales ¥58 million (YoY +1.6%) / Operating profit ¥10 million (YoY +128.7%)
Breakdown of Factors Affecting the Change2025年3月期EBITDA Volume impact Positive / Impact on pricing 為替影響を含めるとプラス / Foreign Exchange Effects ¥76 million / COプラントトラブル・計画停止 ¥-120 million / Operating profit for the fiscal year ended March 2025 Volume impact ¥37 million / Impact on pricing ¥40 million / Other ¥-91 million / Foreign Exchange Effects ¥76 million / EBITDA for the fiscal year ending March 2026 COプラントトラブル解消 ¥120 million / 繰越在庫影響 ¥-92 million / 経費差 ¥-68 million
Key KPIsIndicator name EBITDA / Value ¥1,024 million / Year on year against the same period last year ¥6.5 million, Indicator name ROIC / Value 6.1 % / Year on year against the same period last year -0.2 %, Indicator name ROE / Value 13.8 % / Year on year against the same period last year -3.3 %, Indicator name ROA / Value 6 % / Year on year against the same period last year -1 %, Indicator name EPS / Value ¥181.44 / Year on year against the same period last year ¥-8.2, Indicator name PBR / Value 0.9 times / Year on year against the same period last year Not disclosed, Indicator name PER / Value 7 倍前後 / Year on year against the same period last year Not disclosed
Unit price and quantity metricsセグメント別に数量差・単価差・単価差の内訳として為替影響を掲載。連結売上高では数量差143億円、単価差142億円、単価差内の為替影響210億円
Assumptions Underlying the Business OutlookExchange rate 140 USD/JPY / メタノール・アジアスポット価格 330 USD/ton / Dubai crude oil 75 USD/bbl / Domestic naphtha ¥67,000 /kl / 全世界自動車生産台数 対前年度で微増を想定 / POM中国市場成長率 3〜4
Medium-term management plan targets長期ビジョン『Daicel Vision 4.0』および中期戦略『Accelerate 2025』に沿った事業構造転換・再編を推進。具体的な目標値と実績の対比はNot disclosed
Financial targetsROE Fiscal year ended March 2025: actual 13.8 % / Fiscal year ending March 2026 forecast 14.8 % / ROIC Fiscal year ended March 2025: actual 6.1 % / Fiscal year ending March 2026 forecast 5.4 % / ROA Fiscal year ended March 2025: actual 6 % / Fiscal year ending March 2026 forecast 6.6 % / WACC Fiscal year ended March 2025: actual 4.4 % / Fiscal year ending March 2026 forecast 4.4 %
Annual DividendFiscal year ending March 2025 Annual ¥60 per share / End of period ¥30 per share / Fiscal year ending March 2026 forecast Annual ¥60 per share / Interim ¥30 per share / End of period ¥30 per share
Payout ratioPolicy DOE4%以上かつ総還元性向40%以上 / Fiscal year ended March 2025: actual 63.1 % / Fiscal year ending March 2026 forecast 29.5 % / DOE Fiscal year ended March 2025: actual 4.4 % / Fiscal year ending March 2026 forecast 4.1 %
Acquisition of treasury sharesAcquisition amount ¥150 million / Number of shares acquired 1,098 10,000 shares / Acquisition period 2024年11月〜2025年2月 / Treasury Share Cancellation Number of Shares 1,000 10,000 shares / 消却前発行済み株式総数比 3.61 10,000 shares
Capital expenditures695 億円（2025年3月期実績）／710億円（2026年3月期予想）
New initiativesPOM・LCP・COCの増産投資と新プラント稼働, セイフティ事業米国拠点の購買部門集約・物流効率化・現地調達化, 新規投与デバイスの医療機器薬事承認取得と販売体制構築, サンプルワーク用マイクロ流体デバイスプラントの導入, 半導体後工程へのフォトレジスト材料・接着剤の投入, 欧州EV用途電流遮断器の量産開始, Making 富山フィルタートウ a wholly owned subsidiary
Items this document does not state (10)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

2025年3月期は、エンジニアリングプラスチックを中心とした販売数量の増加や為替影響があったものの、COプラントトラブル、減価償却費の増加などにより営業利益が減少した。2026年3月期は、COプラントトラブル解消などの増益要因がある一方、円高、エンジニアリングプラスチックの減価償却費・定期修繕費用の増加などにより営業利益の減少を見込んでいる。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Presentation Materials for Results for the Fiscal Year Ended March 2025 | Daicel Corporation (4202) timely disclosure | Komori